bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC

JERICHO, N.Y., July 30 /PRNewswire-FirstCall/ -- bioMETRX Inc., (OTC Bulletin Board: BMRX), today announced that it has completed an exclusive 15 year licensing agreement with EZ Print, LLC for the advanced remote printing technology acquired through the company's Sequiam asset purchase agreement.

EZ Print, LLC will invest considerable resources to commercialize and promote the system extensively into the enterprise document production business. Currently the technology branded under the name Print It 123! facilitates remote printing capabilities to large institutions such as Florida State University, Mississippi State University, Volusia County School District and others. Print It 123! allows print shop end users to automatically centralize and route large, costly print jobs to cost efficient "low price per page" industrial printers. The system has provided significant cost benefits to customers since its launch in 2003.

"We were fortunate to find such an experienced group as EZ Print as a licensing partner for the technology. EZ Print brings over 40 years combined print industry experience to the relationship and can open the door to many established distribution channels that can benefit from the technology. EZ Print has made a commitment to drive this technology into the mainstream and turn it into a significant revenue generator," noted Lorraine Yarde, COO at bioMETRX.

Mark Irvin, COO of EZ Print, said, "We think Print It, 123! is probably the greatest print file transport / management system of which few are aware. The product is very mature and the functionality is as robust as any product available today. The ease of set up and competitive pricing of the Print It, 123! solution will enhance its position to become a major player in the print market space in the months and years to come."

"We continue to create value from the recently acquired assets of Sequiam Corporation and have focused on identifying strategic partners to assist in monetizing the assets that service markets outside of our core business model, in order to maximize the potential return," commented Mark Basile, CEO at bioMETRX.

As the global leader in consumer biometric product engineering, development and sales, bioMETRX's technology has proven to be the most dependable and robust consumer biometric platform available today. Its smartTOUCH product line is just starting to make its way into the marketplace, and the company has several new and exciting products that are expected to hit the shelves later this year.

About bioMETRX, Inc.

bioMETRX, Inc. designs, develops and markets biometrics-based products to the consumer market under the common brand name - smartTOUCH

For more information on bioMETRX and/or the company's smartTOUCH line of products, visit the Company website at http://www.biometrx.net.

Safe Harbor Statement: This release may contain certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release with respect to bioMETRX's business, financial condition or results of operations, as well as matters of timing and the prospective terms of any transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond bioMETRX's control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in bioMETRX's filings with the Securities and Exchange Commission. Safe Harbor Statement: This release may contain certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release with respect to bioMETRX's business, financial condition or results of operations, as well as matters of timing and the prospective terms of any transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond bioMETRX's control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in bioMETRX's filings with the Securities and Exchange Commission.

SOURCE bioMETRX Inc.